Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 1;9:2143. doi: 10.1038/s41467-018-04464-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — miR-297a-5p, miR-297b-5p, and miR-297c-5p accumulate in Tet DKO BMMSCs to block Runx2 signaling. a, b The expression of Runx2 in control and Tet DKO BMMSCs was analyzed by western blotting and qPCR. c The levels of miR-297a-5p, miR-297b-5p, or miR-297c-5p in control and Tet DKO BMMSCs assessed by qPCR. d Mineralized nodule formation under osteogenic inductive conditions of Tet DKO BMMSC after miR-297a-5p, miR-297b-5p, or miR-297c-5p inhibitor treatment. e, f The expression levels of osteogenic markers Runx2, ALP, and OCN in Tet DKO BMMSCs after miR-297a-5p, miR-297b-5p, or miR-297c-5p inhibitor treatment, as assessed by qPCR (e) and western blotting (f). g–i Mineralized nodule formation and the expression of Runx2, ALP, and OCN in BMMSCs after miR-297a-5p, miR-297b-5p, and miR-297c-5p mimic treatment as assessed by alizarin red staining (g), qPCR (h) and western blotting (i). *p < 0.05, **p < 0.01, ***p < 0.001 (mean ± SD). Results are from three independent experiments. p values were calculated using two-tailed Student's t test (b, c) and one-way ANOVA (d, e, g, h)